A scar-inhibiting composition containing leukocyte extract and its preparation method

Abstract

The present invention relates to a scar-inhibiting composition containing leukocyte extract and a preparation method thereof, belonging to the technical field of cosmetics. The raw materials of the composition include leukocyte extract, silymarin, Coleus forskohlii root extract, glucosylrutin, snail secretion filtrate, Aralia elata root extract, Theobroma grandiflorum fruit extract, Sedum sarmentosum Bunge extract, carboxymethyl β-glucan sodium and a solvent. In the present invention, Coleus forskohlii root extract, silymarin, glucosylrutin and leukocyte extract are added. The four of them start from promoting the healing of the skin lesion site, inhibiting the massive proliferation of fibroblasts, avoiding scar hyperplasia and inhibiting the dark scar, so that the prepared composition has an excellent scar-inhibiting effect; the addition of snail secretion filtrate, Aralia elata root extract and carboxymethyl β-glucan sodium increases the water replenishing effect of the composition; the combination of Theobroma grandiflorum fruit extract, Sedum sarmentosum Bunge extract and Coleus forskohlii root extract makes the composition have excellent anti-inflammatory effect.

Description

Technical Field

[0001] The present invention belongs to the technical field of cosmetics, and specifically relates to a scar-inhibiting composition containing leukocyte extract and a preparation method thereof. Background Art

[0002] With the rapid development of modern technology, especially the continuous innovation in the field of cosmetics, people's demand for beauty and skin care is increasing day by day, and they are paying more and more attention to the safety and effectiveness of products. Against this background, developing skin care products with multiple functions and high efficiency has become an important trend in the industry. As an emerging biotechnology raw material, leukocyte extract is gradually emerging in the field of cosmetics due to its unique biological activity.

[0003] Scars are the phenomena of abnormal proliferation of fibroblasts and excessive hyperplasia of collagen fibers during the skin wound healing process. Scars not only affect beauty but may also cause functional disorders and itching of local tissues. At present, there are many types of products for reducing scars on the market, but the effects are often not satisfactory, and the treatment cycle is long. In addition, many products have a single performance and can only support scar inhibition without having the functions of moisturizing or anti-inflammatory. Therefore, it is particularly important to develop a composition that can effectively inhibit scar formation and has the functions of moisturizing and anti-inflammatory. Summary of the Invention

[0004] The purpose of the present invention is to provide a scar-inhibiting composition containing leukocyte extract and a preparation method thereof, which solves the problems of poor scar inhibition, moisturizing and anti-inflammatory effects in the prior art.

[0005] The purpose of the present invention can be achieved by the following technical solutions:

[0006] A scar-inhibiting composition containing leukocyte extract, the composition comprising the following raw materials:

[0007] Leukocyte extract, silymarin, Coleus forskohlii root extract, glucosylrutin, snail secretion filtrate, Aralia elata root extract, Theobroma grandiflorum fruit extract, Sedum sarmentosum extract and a solvent.

[0008] Further, the leukocyte extract is 1.4 - 1.6 parts by weight, the silymarin is 2 - 3 parts by weight, the Coleus forskohlii root extract is 2 - 2.5 parts by weight, the glucosylrutin is 4 - 5 parts by weight, the snail secretion filtrate is 2 - 3.5 parts by weight, the Aralia elata root extract is 0.5 - 1 part by weight, the Theobroma grandiflorum fruit extract is 8 - 10 parts by weight, the Sedum sarmentosum extract is 0.6 - 1 part by weight, and the solvent is 55 - 70 parts by weight.

[0009] Further, the solvent includes but is not limited to deionized water, ethylene glycol and glycerol.

[0010] Furthermore, the Coleus forskohlii root extract is obtained by using the dried root of Coleus forskohlii as raw material, 90% alcohol as extraction solvent, and extracting according to the dosage ratio of 1 g of dried Coleus forskohlii root to 10 mL of alcohol by conventional room temperature impregnation method; the Aralia elata root extract is obtained by using the dried root of Aralia elata as raw material, 50% alcohol as extraction solvent, and extracting according to the dosage ratio of 1 g of dried Aralia elata root to 10 mL of alcohol by conventional room temperature impregnation method; the Paullinia cupana fruit extract is obtained by using the fruit of Paullinia cupana as raw material, 30% alcohol as extraction solvent, and extracting according to the dosage ratio of 1 g of Paullinia cupana fruit to 10 mL of alcohol by conventional reflux extraction method; the Sedum sarmentosum extract is obtained by using the dried whole herb of Sedum sarmentosum as raw material, 95% alcohol as extraction solvent, and extracting according to the dosage ratio of 1 g of dried whole herb of Sedum sarmentosum to 10 mL of alcohol by conventional reflux extraction method.

[0011] As a preferred technical solution of the present invention, the composition further comprises sodium carboxymethyl β-glucan.

[0012] Furthermore, the sodium carboxymethyl β-glucan is 4 - 5 parts by weight.

[0013] A preparation method of a scar-inhibiting composition containing white blood cell extract, the preparation method specifically comprises the following steps:

[0014] Mix the white blood cell extract, silymarin, Coleus forskohlii root extract, Aralia elata root extract, Paullinia cupana fruit extract, and Sedum sarmentosum extract evenly to obtain a mixture, mix the mixture and the solvent evenly, then add the remaining raw materials, control the temperature and stir to obtain the finished scar-inhibiting composition.

[0015] As a preferred technical solution of the present invention, the temperature of the temperature-controlled stirring is 26 - 28 °C, and the stirring time is 20 - 30 min.

[0016] An application of a scar-inhibiting composition containing white blood cell extract, characterized in that the scar-inhibiting composition is added to skin care products at a mass percentage of 3 - 5%.

[0017] Furthermore, the skin care products include but are not limited to toner, lotion, and essence.

[0018] The beneficial effects of the present invention:

[0019] (1) The present invention incorporates the extract of Coleus forskohlii roots, silymarin, glucosylrutin, and white blood cell extract. The synergistic effect of these four components endows the prepared composition with excellent scar-inhibiting efficacy. Specifically, the extract of Coleus forskohlii roots, which is rich in triterpenoid compounds and flavonoid compounds, promotes the rapid healing of the skin lesion site and prevents the formation of dark scars; silymarin, whose main components are silybin, silydianin, and isosilybin, inhibits the massive proliferation of fibroblasts derived from keloid tissues; glucosylrutin regulates the TGF-β / Smad signaling pathway to prevent excessive expression that leads to scar hyperplasia; the white blood cell extract rich in bioactive components reverses the dark scar caused by melanin accumulation resulting from the damage of ultraviolet radiation to the skin lesion site. Starting from promoting the healing of the skin lesion site, inhibiting the massive proliferation of fibroblasts, preventing scar hyperplasia, and inhibiting dark scars respectively, the prepared composition has excellent scar-inhibiting efficacy.

[0020] (2) The present invention incorporates the filtrate of snail secretion rich in natural moisturizing factors and hyaluronic acid to maintain the moisture level of the skin; incorporates the extract of Aralia elata roots containing various glycosides of oleanolic acid, Aralia elata saponins, and ginsenosides, etc. to inhibit the decomposition of hyaluronidase; on this basis, carboxymethyl β-glucan sodium is also added to keep the stratum corneum of the skin sufficiently moist, soften and moisten the skin to a certain extent, and at the same time facilitate the absorption of other components in the composition.

[0021] (3) The present invention uses the extract of Theobroma grandiflorum fruits rich in caffeine, alkaloids, tannins, and phenolic substances to inhibit the activity of NF-kB cells and play an anti-inflammatory role to a certain extent; uses the extract of Sedum sarmentosum, which mainly contains flavonoid compounds, sterols, alkaloids, and cyanogenic glycosides, etc., to play an antibacterial role and reduce the probability of the body being infected by bacteria and causing inflammation; at the same time, during the R & D process, the R & D personnel also found that the extract of Coleus forskohlii roots also has antibacterial properties and can assist in strengthening the antibacterial and anti-inflammatory effects of the system to a certain extent; therefore, the combined use of the extract of Theobroma grandiflorum fruits, the extract of Sedum sarmentosum, and the extract of Coleus forskohlii roots can effectively endow the prepared composition with excellent anti-inflammatory effects.

[0022] (4) Wound healing mainly focuses on scar repair, and scar repair is divided into four steps: hemostasis, inflammatory response, cell proliferation, and tissue remodeling. Each step overlaps with each other and is regulated by various factors. The composition prepared by the present invention not only has effective anti-inflammatory and scar-hyperplasia-preventing effects but also has a moisturizing effect. Complementary to each other from three different major dimensions of reducing the adverse effects of the inflammatory response on scar formation, intervening in the formation of scar hyperplasia, and improving the skin moisture state to create favorable conditions for scar repair, the finished product has excellent scar-inhibiting effects. Detailed implementation mode

[0023] Next, in combination with the embodiments of the present invention, the technical solutions in the embodiments of the present invention will be clearly and completely described. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative efforts belong to the scope of protection of the present invention.

[0024] The Coleus forskohlii root extract used in the embodiments of the present invention is obtained by using the dried root of Coleus forskohlii as the raw material and 90% alcohol as the extraction solvent, and extracting by the conventional room temperature impregnation method according to the dosage ratio of the dried root of Coleus forskohlii to alcohol of 1 g:10 mL; the Aralia elata root extract is obtained by using the dried root of Aralia elata as the raw material and 50% alcohol as the extraction solvent, and extracting by the conventional room temperature impregnation method according to the dosage ratio of the dried root of Aralia elata to alcohol of 1 g:10 mL; the Paullinia cupana fruit extract is obtained by using the fruit of Paullinia cupana as the raw material and 30% alcohol as the extraction solvent, and extracting by the conventional reflux extraction method according to the dosage ratio of the fruit of Paullinia cupana to alcohol of 1 g:10 mL; the Sedum sarmentosum extract is obtained by using the dried whole herb of Sedum sarmentosum as the raw material and 95% alcohol as the extraction solvent, and extracting by the conventional reflux extraction method according to the dosage ratio of the dried whole herb of Sedum sarmentosum to alcohol of 1 g:10 mL; the leukocyte extract used is purchased from Shaanxi Aiboni Biotechnology Co., Ltd.; the silymarin used is purchased from Fufeng Snowt Biotechnology Co., Ltd.; the glucosylrutin used is purchased from Jiangsu Boquan Biotechnology Co., Ltd.; the filtrate of snail secretion used is purchased from Guangzhou Pengyuan Chemical Industry Co., Ltd.; the above will not be elaborated hereinafter.

[0025] Example 1

[0026] A scar-inhibiting composition containing leukocyte extract, and the composition comprises the following raw materials in parts by weight:

[0027]

[0028] The preparation method of the scar-inhibiting composition containing leukocyte extract specifically comprises the following steps:

[0029] Mix the leukocyte extract, silymarin, Coleus forskohlii root extract, Aralia elata root extract, Paullinia cupana fruit extract, and Sedum sarmentosum extract evenly to obtain a mixture. Mix the mixture and deionized water evenly, then add the remaining raw materials, control the temperature at 26 °C and stir for 30 min evenly to obtain the finished scar-inhibiting composition.

[0030] Add the scar-inhibiting composition at a mass percentage of 4% to the toner.

[0031] Example 2

[0032] A scar-inhibiting composition containing leukocyte extract, the composition comprising the following raw materials in parts by weight:

[0033]

[0034]

[0035] The preparation method of the scar-inhibiting composition containing leukocyte extract specifically comprises the following steps:

[0036] Mix the leukocyte extract, silymarin, Coleus forskohlii root extract, Aralia elata root extract, Theobroma grandiflorum fruit extract, and Sedum sarmentosum extract evenly to obtain a mixture. Mix the mixture and ethylene glycol evenly, then add the remaining raw materials, control the temperature at 28°C and stir for 25 minutes until evenly mixed, thus obtaining the finished scar-inhibiting composition.

[0037] Add the scar-inhibiting composition at a mass percentage of 3% to the emulsion.

[0038] Example 3

[0039] A scar-inhibiting composition containing leukocyte extract, the composition comprising the following raw materials in parts by weight:

[0040]

[0041] The preparation method of the scar-inhibiting composition containing leukocyte extract specifically comprises the following steps:

[0042] Mix the leukocyte extract, silymarin, Coleus forskohlii root extract, Aralia elata root extract, Theobroma grandiflorum fruit extract, and Sedum sarmentosum extract evenly to obtain a mixture. Mix the mixture and glycerol evenly, then add the remaining raw materials, control the temperature at 27°C and stir for 20 minutes until evenly mixed, thus obtaining the finished scar-inhibiting composition.

[0043] Add the scar-inhibiting composition at a mass percentage of 5% to the essence.

[0044] Example 4

[0045] A scar-inhibiting composition containing leukocyte extract, the composition comprising the following raw materials in parts by weight:

[0046]

[0047] The preparation method of the scar-inhibiting composition containing leukocyte extract specifically comprises the following steps:

[0048] Mix the leukocyte extract, silymarin, Coleus forskohlii root extract, Aralia elata root extract, Theobroma grandiflorum fruit extract, and Sedum sarmentosum extract evenly to obtain a mixed material. Mix the mixed material and ethylene glycol evenly, then add the remaining raw materials, control the temperature at 28°C and stir for 25 minutes until uniform, and thus obtain the finished scar-inhibiting composition.

[0049] Add the scar-inhibiting composition at a mass percentage of 3% to the emulsion.

[0050] Example 5

[0051] A scar-inhibiting composition containing a leukocyte extract, and the composition comprises the following raw materials in parts by weight:

[0052]

[0053]

[0054] The preparation method of the scar-inhibiting composition containing a leukocyte extract specifically comprises the following steps:

[0055] Mix the leukocyte extract, silymarin, Coleus forskohlii root extract, Aralia elata root extract, Theobroma grandiflorum fruit extract, and Sedum sarmentosum extract evenly to obtain a mixed material. Mix the mixed material and ethylene glycol evenly, then add the remaining raw materials, control the temperature at 28°C and stir for 25 minutes until uniform, and thus obtain the finished scar-inhibiting composition.

[0056] Add the scar-inhibiting composition at a mass percentage of 3% to the emulsion.

[0057] Example 6

[0058] A scar-inhibiting composition containing a leukocyte extract, and the composition comprises the following raw materials in parts by weight:

[0059]

[0060]

[0061] The preparation method of the scar-inhibiting composition containing a leukocyte extract specifically comprises the following steps:

[0062] Mix the leukocyte extract, silymarin, Coleus forskohlii root extract, Aralia elata root extract, Theobroma grandiflorum fruit extract, and Sedum sarmentosum extract evenly to obtain a mixed material. Mix the mixed material and ethylene glycol evenly, then add the remaining raw materials, control the temperature at 28°C and stir for 25 minutes until uniform, and thus obtain the finished scar-inhibiting composition.

[0063] Add the scar-inhibiting composition at a mass percentage of 3% to the emulsion.

[0064] Comparative Examples 1-4

[0065] Compared with Example 5, the difference lies in that the weight parts of white blood cell extract, silymarin, Coleus forskohlii root extract and glucosylrutin in Comparative Examples 1-4 are shown in Table 1, and the remaining parameters and operation steps remain unchanged.

[0066] Table 1

[0067]

[0068] Comparative Examples 5-7

[0069] Compared with Example 5, the difference lies in that the weight parts of filtrate of snail secretion, Aralia elata root extract and carboxymethyl β-glucan sodium in Comparative Examples 5-7 are shown in Table 2, and the remaining parameters and operation steps remain unchanged.

[0070] Table 2

[0071]

[0072] Comparative Examples 8-10

[0073] Compared with Example 5, the difference lies in that the weight parts of Eugenia uniflora fruit extract, Sedum sarmentosum extract and Coleus forskohlii root extract in Comparative Examples 8-10 are shown in Table 3, and the remaining parameters and operation steps remain unchanged.

[0074] Table 3

[0075]

[0076] Test Example 1

[0077] Human safety test method: Refer to the human skin patch test method in Section 2, Chapter 7 of the "Technical Specifications for Cosmetics Safety" (2015 Edition) to test the skin occlusive patch test.

[0078] (1) Test samples: The finished scar-inhibiting compositions prepared in Examples 1-6 and Comparative Examples 1-10 were respectively added to the ordinary emulsion external use matrix to prepare test samples, wherein the finished scar-inhibiting composition accounted for 3% of the total mass of the emulsion. At the same time, 2% hydroquinone ointment was used as the control group, and the ordinary emulsion external use matrix was used as the blank group.

[0079] (2) Selection of test subjects: Volunteers aged 18 - 60 years who meet the test requirements are selected as the subjects. The following groups of people cannot be subjects: those who have used antihistamines in the past week or immunosuppressants within the past month; those who have applied any anti-inflammatory drugs to the test site within the past two months; subjects with inflammatory skin diseases that have not healed clinically; insulin-dependent diabetic patients; patients with asthma or other chronic respiratory diseases who are receiving treatment; those who have received anti-cancer chemotherapy within the past 6 months; immunodeficient or autoimmune disease patients; lactating or pregnant women; those who have had bilateral mastectomies and bilateral axillary lymph node resections; those whose test results are affected by scars, pigmentation, atrophy, nevus flammeus, or other defects at the skin test site; those who are participating in other clinical trials; those with highly sensitive constitutions; non-volunteers or those who cannot complete the specified content according to the test requirements.

[0080] (3) Test method: Fifty suitable subjects are selected, including 30 females and 20 males. Qualified patch test devices with an area not exceeding 50 mm 2 and a depth of about 1 mm are used. The test sample is placed in the small chamber of the patch test device, and the dosage is 0.020 g. The patch test device with the test sample is applied to the flexor side of the forearm of the subject with a low-allergy tape, and gently pressed with the palm to make it evenly adhere to the skin for 24 hours. At 30 minutes (after the indentation disappears), 24 hours, and 48 hours after removing the patch test device with the test sample, observe the skin reaction according to the criteria in Table 4 and record the observation results, as shown in Table 5.

[0081] Table 4 Grading criteria for skin reactions in skin closed patch test

[0082]

[0083] Table 5 Patch test scores

[0084]

[0085]

[0086] It can be seen from the results in Table 5 that the finished scar-inhibiting compositions prepared in Examples 1 - 6 and Comparative Examples 1 - 10 all show negative reactions, meeting the requirements for human safety, having a certain feasibility, and meeting the basic requirements of cosmetics. Therefore, they can all be used as comparison objects for experimental effects in subsequent experiments.

[0087] Test Example 2

[0088] Take 96 mice, with 48 males and 48 females, each weighing 30 - 35 g, and randomly divide them into 8 groups. Each group consists of 6 female mice and 6 male mice, for a total of 12 mice. All the mice are depilated and disinfected; the mice are tied up and anesthetized by a combination of intramuscular injection of Sumianxin and intravenous injection of sodium pentobarbital. Use a YLS-5Q scalding instrument to prepare a scald wound in the center and on both sides of the back of each mouse. The wound area is 2 cm 2 , and the scalding conditions are: the temperature of the scalding head is 100 °C, the acting pressure is 800 g, and the contact time between the scalding head and the mouse skin is 4 s. Antibiotics are administered by gastric gavage 2 h after the modeling is completed to prevent infection at the scalded area of the mouse. After 30 days, the scalds of all the mice have healed, and during this process, no mice died in all the groups.

[0089] Set up a blank group, three experimental groups, and four control groups; the blank group is normal saline, the three experimental groups respectively use the scar-inhibiting compositions prepared in Examples 4 - 6, and the control groups 1 - 4 respectively use the scar-inhibiting compositions prepared in Comparative Examples 1 - 4.

[0090] After all the mice's scalds have healed (i.e., starting from the 30th day), the blank group applies normal saline to the scalded area of the mice every day, and the experimental groups and the control groups apply the corresponding scar-inhibiting compositions to the scalded area of the mice every day. The usage method is to apply it twice a day at 8:00 am and 8:00 pm, and the application amount is 2 g, and it is continuously applied for 28 days. Taking the scar area on the 30th day as the original scar area and the scar area on the 58th day as the current scar area, record and measure the area of the scalded area, and calculate the scar removal rate:

[0091] Scar removal rate = (Original scar area - Current scar area) / Original scar area × 100%;

[0092] The results are shown in Table 6.

[0093] Table 6 Scar removal rate

[0094] Scar removal rate (%) Blank group 18.48 Example 4 92.59 Example 5 94.83 Example 6 93.24 Comparative example 1 73.87 Comparative example 2 78.22 Comparative example 3 81.88 Comparative example 4 80.46

[0095] As can be seen from Table 6, the scar-inhibiting composition prepared by the present invention has an excellent scar-inhibiting effect. This is because the present invention adds Coleus forskohlii root extract, silymarin, glucosyl rutin, and leukocyte extract, which respectively start from promoting the healing of the skin lesion site, inhibiting the massive proliferation of fibroblasts, avoiding scar hyperplasia, and inhibiting dark scar marks, making the prepared composition have an excellent scar-inhibiting effect.

[0096] Test Example 3

[0097] Hydration test: The scar-inhibiting compositions prepared in Examples 4-6 and Comparative Examples 5-7 were added to the same emulsion with the same matrix at 3% by mass of the total mass of the emulsion to obtain test samples. 72 subjects aged 30-45 with frequent skin dryness and water shortage problems, regardless of gender, were randomly invited and divided into 6 groups, with 12 subjects in each group. The test samples prepared from the scar-inhibiting compositions prepared in Examples 4-6 and Comparative Examples 5-7 were used respectively. The usage method was to take 1 mg / cm 2 of the test sample and evenly apply it to the entire face after cleansing in the morning and evening, and gently massage until absorbed for one cycle, and one cycle was 28 days.

[0098] The capacitance method for measuring the water content of the human stratum corneum is based on the significant difference in the dielectric constants of water and other substances. According to the different water contents of the stratum corneum, the measured capacitance values of the skin are different, and its parameters can represent the skin water content;

[0099] Therefore, before use and after 28 days of use, the forehead area of the subjects was selected as the test area, and the skin water content was detected 3 times using the skin water content tester Corneometer CM825 and the average value was taken to calculate the change in the skin water content before and after using the test sample. The results are shown in Table 7.

[0100] Table 7 Water content growth rate

[0101] Moisture content on day 0 Moisture content on day 28 Moisture content growth rate (%) Example 4 31.83 47.62 49.61 Example 5 32.68 49.39 51.13 Example 6 32.42 48.81 50.56 Comparative example 5 31.40 40.95 30.41 Comparative example 6 32.05 43.54 35.85 Comparative example 7 31.23 43.71 39.96

[0102] It can be seen from Table 7 that the scar-inhibiting composition prepared by the present invention has outstanding hydration and moisturizing effects.

[0103] Test Example 4

[0104] The scar-inhibiting compositions prepared in Examples 4-6 and Comparative Examples 8-10 were added to the same emulsion with the same matrix at 3% by mass of the total mass of the emulsion to obtain test samples. 72 volunteers aged 23-40 with acne inflammation on the face were invited, regardless of gender, and randomly divided into 6 groups, with 12 volunteers in each group. The test samples prepared from Examples 4-6 and Comparative Examples 8-10 were used respectively; the usage method was to apply the test sample to the entire face with a thickness of about 0.5 mm, once in the morning and once in the evening every day, and continuously used for one cycle, and one cycle was 21 days; the overall condition of the acne inflammation on the face of each volunteer before and after use was uniformly evaluated by the same dermatologist, and it was recorded and scored in a timely manner. The average value of the scoring data of 12 people in each group was used as the final result;

[0105] Facial acne inflammation scoring standard: 0 points (no acne inflammation on the face);

[0106] 1 point (about 10% of the facial area has acne inflammation);

[0107] Grade 2 (about 20% of the facial area has acne inflammation);

[0108] Grade 3 (about 30% of the facial area has acne inflammation);

[0109] Grade 4 (about 40% of the facial area has acne inflammation);

[0110] Grade 5 (more than 50% of the facial area has acne inflammation);

[0111] The results are shown in Table 8.

[0112] Table 8

[0113] Acne inflammation score on day 0 Acne inflammation score on day 21 Example 4 4.17 0.75 Example 5 4.25 0.67 Example 6 4.25 0.83 Comparative example 8 4.17 2.08 Comparative example 9 4.25 1.92 Comparative example 10 4.17 1.58

[0114] As can be seen from Table 8, the scar-inhibiting composition prepared by the present invention has excellent anti-inflammatory effects.

[0115] In the description of the specification, the descriptions referring to terms such as "one embodiment", "example", "specific example", etc. mean that the specific features, structures, materials or characteristics described in connection with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in a suitable manner in any one or more embodiments or examples.

[0116] The above content is only an example and illustration of the present invention. Those skilled in the art of the present technology can make various modifications or supplements to the described specific embodiments or use similar ways to replace them. As long as they do not deviate from the invention or exceed the scope defined by the claims of the present invention, they should fall within the protection scope of the present invention.

Claims

1. A scar inhibiting composition containing a leukocyte extract, characterized in that: The composition comprises the following raw materials: Leukocyte extract, silymarin, Coleus forskohlii root extract, glucosylrutin, snail secretion filtrate, Aralia elata root extract, Theobroma cacao fruit extract, Herba scutellariae extract and solvent; The leukocyte extract is 1.4-1.6 parts by weight, the silymarin is 2-3 parts by weight, the Coleus forskohlii root extract is 2-2.5 parts by weight, the glucosylrutin is 4-5 parts by weight, the snail secretion filtrate is 2-3.5 parts by weight, the Aralia elata root extract is 0.5-1 parts by weight, the Brazilian cocoa fruit extract is 8-10 parts by weight, the Herba Creepersii extract is 0.6-1 parts by weight, and the solvent is 55-70 parts by weight; The Coleus forskohlii root extract is obtained by using the dried root of Coleus forskohlii as a raw material, using 90% alcohol as an extraction solvent, and extracting it by a conventional room temperature immersion method at a ratio of 1 g:10 mL of the dried root of Coleus forskohlii to the alcohol; the Aralia elata root extract is obtained by using the dried root of Aralia elata as a raw material, using 50% alcohol as an extraction solvent, and extracting it by a conventional room temperature immersion method at a ratio of 1 g:10 mL of the dried root of Aralia elata to the alcohol; the Paullinia cupana fruit extract is obtained by using 30% alcohol as an extraction solvent, and extracting it by a conventional reflux extraction method at a ratio of 1 g:10 mL of the Paullinia cupana fruit; the Sedum scabra extract is obtained by using Sedum scabra (Sedum elata) as a raw material, using 50% alcohol as an extraction solvent, and extracting it by a conventional room temperature immersion method at a ratio of 1 g:10 mL of the dried root of Aralia elata to the alcohol; The dried whole herb of Scutellaria sarmentosum was used as raw material, 95% alcohol was used as extraction solvent, and the dosage ratio of the dried whole herb of Scutellaria sarmentosum to alcohol was 1g:10mL, and the extraction was performed by conventional reflux extraction method.

2. The scar-inhibiting composition containing leukocyte extract according to claim 1, characterized in that: The solvent is deionized water, ethylene glycol and glycerol.

3. The scar-inhibiting composition containing leukocyte extract according to claim 1, characterized in that: The composition also includes sodium carboxymethyl beta-glucan.

4. The scar-inhibiting composition containing leukocyte extract according to claim 3, characterized in that: The sodium carboxymethyl β-glucan is 4-5 parts by weight.

5. A method for preparing a scar-inhibiting composition containing a leukocyte extract according to any one of claims 3 to 4, characterized in that: The preparation method specifically comprises the following steps: The leukocyte extract, silymarin, Coleus forskohlii root extract, Aralia elata root extract, Theobroma cacao fruit extract and Scutellaria baicalensis extract are mixed evenly to obtain a mixture, the mixture and a solvent are mixed evenly, and the remaining raw materials are added, and the temperature is controlled and stirred to obtain a finished product of the scar inhibition composition.

6. The method for preparing the scar-inhibiting composition containing leukocyte extract according to claim 5, characterized in that: The temperature of the temperature-controlled stirring is 26-28° C., and the stirring time is 20-30 min.

Images